Biggest News Aggregation in the World

Easd 2023 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Easd 2023. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Easd 2023 Today - Breaking & Trending Today

Tirzepatide Bests Semaglutide For A1c, Weight Loss in Indirect Comparison of Clinical Trial Data - Vimarsana News

Tirzepatide Bests Semaglutide For A1c, Weight Loss in Indirect Comparison of Clinical Trial Data

Published: September 25, 2023

A network meta-analysis suggests tirzepatide may be more effective than semaglutide in reducing HbA1c and body weight in type 2 diabetes but may increase gastrointestinal adverse events, especially at higher doses.

Source: hcplive.com

Related Topics:

United States Thomas Karagiannis Aristotle University Of Thessaloniki Novo Nordisk Office Of The Commissioner American Diabetes Association European Association For The Study Of Diabetes Cochrane Library Drug Administration European Association Aristotle University Mean Difference Confidence Interval Risk Ratio Accessed September Chronic Weight Management Easd 2023

For Older Patients, Low-Dose Aspirin Could Reduce Diabetes Risk by 15% - Vimarsana News

For Older Patients, Low-Dose Aspirin Could Reduce Diabetes Risk by 15%

Published: August 31, 2023

Using data from the ASPREE trial, a new study from EASD 2023 suggests use of low-dose aspirin in older adults could reduce the risk of developing type 2 diabetes.

Source: hcplive.com

Related Topics:

South Australia United States Sophia Zoungas School Of Public Health Preventive Medicine At Monash University Annual Meeting European Association Public Health Preventive Medicine Monash University New England Journal All Cause Mortality Aspirin And Type 2 Diabetes Diabetes And Aspirin Easd 2023